Abdel-Fatah et al. [20] reported that Bcl-2 negativity in triple-negative breast cancer was associated with a 2-fold increased risk of death (HR = 1.71; 95%-CI 1.21–2.41; p = 0.002) and recurrence (HR = 1.79; 95%-CI 1.34–2.38; p = 0.0005); in multivariate survival analysis, Bcl-2 negativity was also associated with worse cancer-specific survival and progression-free survival independently of the nodal stage. Here, BCL2 is linked to triple-negative breast carcinoma.